Browse by author
Lookup NU author(s): Dr April Phaw, Dr Jess Dyson, Professor David Jones
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Primary biliary cholangitis (PBC) is a progressive inflammatory autoimmune cholestatic liver disease. Without treatment, it may result in fibrosis and eventually end stage liver disease. In addition to the disease burden, the symptom impact on the quality of life for PBC patients is significant. Ursodeoxycholic acid, and the second-line therapy, Obeticholic acid, are the only available licensed treatments. Although there has been rapid development of novel therapies in recent years for the treatment of PBC, there are very few symptoms directed therapies. Area covered: This literature review aims to review the current treatment landscape in PBC and to explore how the next few years may unfold in the field. The current guidelines and emerging therapies in phase 2, 3 and 4 clinical trials have been included. Expert opinion: The currently available therapies are effective, but their use has limitations and challenges and there is still significant unmet need. Although there have been promising therapeutic interventions in recent years, further research into personalizing therapeutic strategies with available treatments and new agents is needed.
Author(s): Phaw NA, Dyson JK, Jones D
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Emerging Drugs
Year: 2020
Volume: 25
Issue: 2
Pages: 101-112
Online publication date: 07/04/2020
Acceptance date: 01/04/2020
ISSN (print): 1472-8214
ISSN (electronic): 1744-7623
Publisher: Taylor and Francis Ltd
URL: https://doi.org/10.1080/14728214.2020.1751814
DOI: 10.1080/14728214.2020.1751814
PubMed id: 32253941
